Table 3 circRNA candidates validated as significantly associated with prostate cancer aggressiveness in both cohorts
From: The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer
pT2 vs. pT3-4 | Correlation to GG | BCR vs. recurrence-free | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RP Cohort 1 | RP Cohort 3 | RP Cohort 1 | RP Cohort 3 | RP Cohort 1 | RP Cohort 3 | |||||||
circRNA | P value | FC | P value | FC | P value | Tau | P value | Tau | P value | FC | P value | FC |
circMKLN1 | 0.01 | − 1.34 | 0.58 | − 1.11 | 0.21 | − 0.08 | 0.03 | − 0.13 | 0.001 | − 1.41 | 0.04 | − 1.30 |
circZNF532 | 0.002 | − 1.55 | 0.001 | − 1.35 | 0.08 | − 0.12 | 0.14 | − 0.08 | 0.01 | − 1.43 | 0.23 | − 1.12 |
circMAN1A2 | 0.003 | − 1.36 | 0.03 | − 1.12 | 0.03 | − 0.15 | 0.36 | − 0.05 | 0.15 | − 1.22 | 0.85 | 1.00 |
circSEMA3C | 0.001 | − 1.55 | 0.77 | 1.00 | 0.01 | − 0.17 | 0.03 | − 0.13 | 0.28 | − 1.25 | 0.85 | 1.04 |
circLPAR3 | 0.01 | − 1.46 | 0.01 | − 1.40 | 0.03 | − 0.15 | 0.31 | − 0.06 | 0.37 | − 1.24 | 0.11 | − 1.12 |
circCDYL2 | 0.04 | − 1.17 | 0.01 | − 1.33 | 0.03 | − 0.14 | 0.21 | − 0.07 | 0.09 | − 1.26 | 0.19 | − 1.15 |
circELK4 | 0.02 | − 1.31 | 0.01 | − 1.33 | 0.06 | − 0.13 | 0.03 | − 0.12 | 0.11 | − 1.19 | 0.22 | − 1.18 |
circFAT3 | 0.01 | − 1.60 | 0.06 | − 1.47 | 0.01 | − 0.17 | 0.01 | − 0.15 | 0.22 | − 1.20 | 0.05 | − 1.25 |
circSLC45A4 | 0.01 | − 1.49 | 0.61 | − 1.01 | 0.003 | − 0.20 | 0.02 | − 0.13 | 0.42 | − 1.09 | 0.10 | − 1.17 |